Adherex Technologies (NASDAQ:FENC) Announces Quarterly Earnings Results

Adherex Technologies (NASDAQ:FENC) announced its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.12), Zacks reports. The firm had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.73 million.

Here are the key takeaways from Adherex Technologies’ conference call:

• Record net product sales of $44.6 million in 2025 (Q4 $13.8M, +75% YoY) driven by quarter-over-quarter active patient growth, higher conversion rates (70% in Q4 vs 50% in Q1), and expanding account penetration.
• The company settled U.S. patent litigation with Cipla, delaying generic entry until September 1, 2033, which management says provides multi‑year market exclusivity and will save “multiple millions” in annual G&A to redeploy into growth.
• Medical evidence and KOL engagement accelerated with new real‑world and investigator‑initiated studies (including City of Hope, Tampa General, and the Japan STS‑J01 trial) supporting broader use of PEDMARK in adults and AYA patients and enabling potential label/guideline expansion.
• Management is expanding commercial and medical headcount and expects cash operating expenses to rise from ~$35M in 2025 to ~$50M in 2026, with the company forecasting material commercial contribution in H2 2026 and positive cash flow early in 2026.

Adherex Technologies Stock Performance

Shares of FENC stock opened at $6.17 on Thursday. Adherex Technologies has a fifty-two week low of $4.68 and a fifty-two week high of $9.92. The firm has a market capitalization of $212.00 million, a price-to-earnings ratio of -18.15 and a beta of 0.75. The stock’s 50-day simple moving average is $7.89 and its 200-day simple moving average is $8.12.

Insider Activity at Adherex Technologies

In related news, Director Rosty Raykov sold 10,349 shares of Adherex Technologies stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $7.76, for a total value of $80,308.24. Following the completion of the sale, the director directly owned 98,477 shares in the company, valued at $764,181.52. This trade represents a 9.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.76% of the stock is owned by insiders.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new stake in Adherex Technologies stock. Jane Street Group LLC purchased a new stake in Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned approximately 0.05% of Adherex Technologies as of its most recent SEC filing. 55.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FENC. Piper Sandler initiated coverage on Adherex Technologies in a research report on Friday, January 9th. They set an “overweight” rating and a $18.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a report on Thursday, January 22nd. Zacks Research raised shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a research report on Friday, December 12th. Wall Street Zen cut shares of Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Finally, B. Riley Financial began coverage on shares of Adherex Technologies in a research note on Thursday, February 12th. They issued a “buy” rating and a $16.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Adherex Technologies has an average rating of “Moderate Buy” and a consensus target price of $15.25.

Key Adherex Technologies News

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: Company press release: reported record annual product revenue and strong year-over-year growth in net product sales (Net PEDMARK® product sales $44.6M for FY2025, 50% y/y; Q4 net product sales $13.8M, +75% y/y), highlighting underlying top-line momentum. Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Quarterly materials and call transcript are available for deeper read of management commentary and guidance; investors should review the call for color on margins, product cadence, and FY2026 outlook. Fennec Pharmaceuticals Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Media note: a preview item flagged the company as “projected to post earnings,” which is informational rather than market-moving by itself. Adherex Technologies (FENC) Projected to Post Earnings on Wednesday
• Neutral Sentiment: Short-interest reports appearing in filings show zero reported short shares (and nonsensical NaN changes) across several updates — this appears to be noisy or incomplete data rather than a clear short-squeeze signal; continue to monitor FINRA/Exchange reports for confirmed short-interest figures.
• Negative Sentiment: Earnings miss: reported Q4 EPS of ($0.11) vs. consensus ~$0.01 and revenue $13.78M vs. ~$14.73M — an earnings and revenue shortfall that explains downward pressure on fundamentals and may weigh on near-term sentiment. Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Shareholder/legal risk: a law firm outreach (Johnson Fistel) is encouraging shareholders to contact them about potential claims — this is an early-stage investor-litigation indicator that can create headline risk and potential legal costs. Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.